UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 9, 2011

CARDIOGENESIS CORPORATION

(Exact name of registrant as specified in its charter)

California (State or other jurisdiction of incorporation)		000-28288 (Commission File Number)		77-0223740 (IRS Employer Identification No.)

11 Musick
Irvine, CA 92618
(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (949) 420-1800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 2.02		Results of Operation and Financial Condition

On March 9, 2011, Cardiogenesis Corporation (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2010. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Also on March 9, 2011, the Company held a conference call with analysts and investors to report its financial results for the quarter and fiscal year ended December 31, 2010. The transcript of the conference call is furnished as Exhibit 99.2 and is incorporated herein by reference.

The information in this Form 8-K, including Exhibits 99.1 and 99.2, are furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01		Financial Statements and Exhibits

     (d) Exhibits

Exhibit Number				Description
	99.1			Press release of Cardiogenesis Corporation dated March 9, 2011.
	99.2			Conference Call Transcript dated March 9, 2011.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit Index

Exhibit Number				Description
	99.1			Press release of Cardiogenesis Corporation dated March 9, 2011.
	99.2			Conference Call Transcript dated March 9, 2011.